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Leucine-rich repeat kinase 2 (LRRK2) is a large multidomain protein
with both a Ras of complex (ROC) domain and a kinase domain
(KD) and, therefore, exhibits both GTPase and kinase activities.
Human genetics studies have linked LRRK2 as a major genetic
contributor to familial and sporadic Parkinson’s disease (PD), a neu-
rodegenerative movement disorder that inflicts millions worldwide.
The C-terminal region of LRRK2 is a Trp-Asp-40 (WD40) domain with
poorly defined biological functions but has been implicated in micro-
tubule interaction. Here, we present the crystal structure of the
WD40 domain of human LRRK2 at 2.6-Å resolution, which reveals a
seven-bladedWD40 fold. The structure displays a dimeric assembly in
the crystal, which we further confirm by measurements in solution.
We find that structure-based and PD-associated disease mutations in
the WD40 domain including the common G2385R polymorphism
mainly compromise dimer formation. Assessment of full-length
LRRK2 kinase activity by measuring phosphorylation of Rab10, a
member of the family of Rab GTPases known to be important kinase
substrates of LRRK2, shows enhancement of kinase activity by sev-
eral dimerization-defective mutants including G2385R, although di-
merization impairment does not always result in kinase activation.
Furthermore, mapping of phylogenetically conserved residues onto
the WD40 domain structure reveals surface patches that may be
important for additional functions of LRRK2. Collectively, our analy-
ses provide insights for understanding the structures and functions
of LRRK2 and suggest the potential utility of LRRK2 kinase inhibitors
in treating PD patients with WD40 domain mutations.
LRRK2 | WD40 | crystal structure | Parkinson’s disease
Parkinson’s disease (PD) is a severe neurodegenerative dis-order that often inflicts older people, for which there is
neither an objective test for diagnosis nor an effective cure.
About 1–2% of the population above age 65 in the world live
with PD (1). The cause of PD is unknown, but current research
links it to age and certain genetic mutations. To date, mutations
in leucine-rich repeat kinase 2 (LRRK2) represent a major ge-
netic contributor to familial and sporadic PD (2–4). The exact
physiological function of LRRK2 is not clear although it has
been shown to interact with many partner proteins such as mi-
crotubules and apoptotic pathway players and contribute to
many cellular processes (5, 6). For examples, LRRK2 regulates
neurite growth and neurons that express PD-associated LRRK2
mutations show a progressive reduction in neurite length and
branching (5, 7). These neurons additionally display phospho-
tau–positive inclusions and ultimately undergo apoptosis (5, 7).
LRRK2 is a large multidomain protein with 2,527 amino acids
(286 kDa) and consists of armadillo repeats (ARM), ankyrin
repeats (ANK), leucine-rich repeats (LRR), Ras of complex
(ROC), C-terminal of ROC (COR), kinase domain (KD), and
the Trp-Asp-40 (WD40) domain (5) (Fig. 1A). LRRK2 has
bienzymatic activities of GTPase and kinase. The kinase activity
is generally believed to be important in the pathogenesis of PD
(7). The most frequent mutation, G2019S in the kinase domain,
increases the kinase activity by about twofold, and GTP binding
to the ROC domain may regulate kinase activity (5, 8–10). The
crystal structure of ROC bound with GDP and Mg2+ showed a
domain-swapped dimeric architecture (9). However, subsequent
biochemical studies suggest that the ROC domain is a stable and
catalytically active monomer in solution, suggesting that the do-
main swapping may be an artifact of construct or crystallization
(11). Consistently, cellular imaging showed that LRRK2 is pre-
dominantly monomeric throughout the cytosol but can also form
oligomers (12). A recent low-resolution structural model of full-
length LRRK2 dimer was reported by negative-staining EM and
other methods, in which the ROC and COR domains were
interpreted as mediating the dimerization (13, 14). In addition,
crystal structure of a ROC-COR construct of Roco, a pro-
karyotic homolog of LRRK2, revealed a COR domain mediated
dimer (15), and full-length Roco undergoes dynamic monomer-
dimer transition during GTP turnover (16). Therefore, di-
merization is a central question in LRRK2 structure and function.
The C-terminal WD40 domain of LRRK2 is required for
LRRK2-induced neurotoxicity (17, 18) and has been shown to
mediate the interaction of LRRK2 with microtubules and syn-
aptic vesicles (19, 20). Many PD mutations enhance the micro-
tubule association of LRRK2, forming filamentous aggregates in
cells (19). A WD40 domain variant, G2385R, which is a risk
factor for PD in ethnic Chinese and/or Asian patients, with an
unknown mechanism of action (21, 22), correlates with an al-
tered strength and quality of interactions to synaptic vesicles,
resulting in perturbed vesicular trafficking (20, 23). Unlike
G2019S with enhanced kinase activity, one study has reported
that the G2385R mutation may result in partial loss of kinase
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function (24), suggesting a pathogenic mechanism different from
kinase-activating LRRK2 mutations (25). Additional WD40 domain
variants have also been reported as associated with PD risk (26–31).
Here, we report the crystal structure of human LRRK2 WD40
domain determined at 2.6-Å resolution. The structure reveals a
canonical seven-bladed WD40 fold and a surprising dimeric state
in the crystal. We confirmed that isolated WD40 domain forms
concentration-dependent dimers in solution and that structure-
based interface mutations mainly disrupt the dimerization. Nota-
bly, the WD40 domain mutation G2385R is located at the
dimerization interface and compromised dimerization. In contrast
to previously identified reduction in kinase activity, our data on
Rab10 phosphorylation indicated an enhanced kinase activity,
supporting the overarching hypothesis that pathogenesis of PD is
mediated through hyperactivation of LRRK2. Similar to G2385R,
two structure-based mutants H2391D and R2394E at the WD40
dimerization interface also increased LRRK2 kinase activity. We
further mapped sequence conservation onto the WD40 domain
structure and found surface patches that may be important for
additional functions of LRRK2.
Results
Overall Structure of the Human LRRK2 WD40 Domain. We expressed
the WD40 domain of human LRRK2 (residue 2142–2527) in
insect Sf9 cells. The protein was purified, and diffracting crystals
were obtained. We initially attempted molecular replacement
structure determination of the LRRK2 WD40 domain using
multiple known WD40 domain structures in the Protein Data
Bank (PDB). No viable solution was obtained, likely because of
the weak homology between the LRRK2 WD40 domain and
WD40 domain structures in the PDB. We therefore searched for
heavy atom derivatives using soaking of preformed native crys-
tals. After screening 13 heavy atom compounds (SI Appendix,
Table S1), diffraction data collected on a crystal soaked with
transplatinum (II) diammine dichloride gave sufficient anoma-
lous signals at the wavelength of 0.98 Å, which is a high energy
remote wavelength of the platinum L-III edge. A total of three
platinum sites were identified (SI Appendix, Fig. S1A). We de-
termined the WD40 domain crystal structure using the single
wavelength anomalous diffraction (SAD) method and refined it to
2.6-Å resolution (SI Appendix, Table S2). The ordered part of the
structure extends from residue 2,142 to residue 2,498 and has a
few gaps, and the last 30 residues in the construct are disordered.
The structure shows a canonical seven-bladed WD40 domain
architecture (Fig. 1B), with a prominent hole in the middle when
viewed from the top (Fig. 1C), within which the platinum com-
pound molecules are bound (SI Appendix, Fig. S1A). The elec-
trostatic potential plot reveals a highly charged surface with
positively and negatively charged patches (Fig. 1C). A structural
homology search in DALI (32) revealed that it is most similar to
the WD40 domains in the mRNA export factor Rae1 (PDB ID
code 4OWR) (33), the apoptotic protein Apaf-1 (PDB ID code
3SHF) (34), the anaphase promoting complex (APC) protein
CDH1 (PDB ID code 5A31) (35), and the coatomer subunit
β′-COP (PDB ID code 4J84) (36) (SI Appendix, Fig. S1 B–E). All
blades comprise four anti-parallel β-strands. The first six blades
run from β2–β5, β6–β9, β10–β13, β14–β17, β18–β21, and β22–β25
continuously, and the last and seventh blade contains β26–β28
Fig. 1. Structural overview. (A) Domain organization of LRRK2. The residue boundary of the WD40 domain and locations of three recurrent disease mu-
tations are marked. (B) Ribbon diagram using rainbow gradient color from blue at the N terminus to red at the C terminus. The locations of the seven blades
are marked. Two views are shown. (C) Electrostatic surface diagram showing a prominent hole in the middle of the structure. (D) Mapping of sequence
conservation onto the WD40 domain structure. The view of the bottom surface is at the same orientation as B, Left.
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and β1 from the N-terminal end to complete the fold, forming a
stabilized ring-like structure (Fig. 1B and SI Appendix, Fig. S2).
LRRK2 WD40 domain sequences from different species are
aligned and compared (SI Appendix, Fig. S2). Previous structural
and biochemical studies have indicated that one surface (top) of
the WD40 domain is more frequently used for protein–protein
interactions than the opposing surface (37), and a highly con-
served surface on a β-propeller is almost always involved in
protein–protein interactions (38). We therefore mapped sequence
conservation onto the WD40 domain structure of LRRK2 (Fig.
1D). This exercise revealed surface patches that are completely
or partially conserved across the aligned species. In particular,
there is a relatively large conserved patch on the top surface of
the LRRK2 WD40 domain formed by residues in blades III and
IV (Fig. 1D), suggesting additional functions of the domain in
LRRK2 biology. In comparison, the dimerization surface is not
as conserved (Fig. 1D and below).
Dimerization of the WD40 Domain. There are two WD40 domain
monomers in the crystallographic asymmetric unit, which are
related by an almost perfect twofold axis (176.3°) (Fig. 2A). The
interactions are centered at blade V but also involve the sur-
rounding structures as well as blade IV and VI (Fig. 2A and SI
Appendix, Fig. S2). The dimerization interface is large and buries
approximately ∼1,200 Å2 surface area per monomer. Residues
that bury more than 40 Å surface areas are marked (SI Appendix,
Fig. S2). In addition to surface area burial, a number of potential
hydrogen bonding and salt bridge interactions exist, among
D2388 of one subunit and H2391 and S2345 of the symmetric
subunit, among R2394 of one subunit and main chain atoms of
M2408 and Y2410 of the symmetric subunit, and between E2395
of one subunit and Y2346 of the symmetric subunit (Fig. 2B).
Given the dimeric association of the WD40 domain in the
crystal, we determined whether it also forms dimers in solution.
We used multiangle light scattering (MALS) to measure the
molecular mass of the MBP-tagged LRRK2 WD40 domain as it
eluted from an in-line size exclusion column. The calculated
molecular mass of an MBP-tagged LRRK2 WD40 domain
monomer is roughly ∼83 kDa. The MALS measurement showed
that the LRRK2 WD40 domain peak when injected at 2 mg/mL
corresponded to 164.0 kDa (2% error) in molecular mass, corre-
sponding to a dimer (Fig. 2C). Therefore, the WD40 domain dimer
observed in the crystal is also a bona fide dimer in solution, instead
of a crystallization artifact. Further gel filtration chromatography
analysis at different concentrations of the LRRK2 WD40 domain
showed that it is a dynamic, concentration-dependent dimer, with
the peak shifting to later elution positions when serially diluted
from 2 mg/mL to 0.25 mg/mL (Fig. 2D). In particular, the measured
molecular mass of the LRRK2 WD40 domain peak when injected
at 0.25 mg/mL was 115.2 kDa (2% error), smaller than a dimer and
closer to a monomer of MBP-tagged LRRK2 WD40 (Fig. 2C).
Structure-Based Mutations and PD-Associated Variants in the WD40
Domain. We next identified residues that may be important for
dimerization based on the structure (SI Appendix, Fig. S2) and
investigated whether mutations on these residues affect the di-
merization of the LRRK2 WD40 domain in solution (Fig. 3 A–G
and SI Appendix, Table S3). Using gel filtration chromatography
and matched with concentrations, WD40 domain mutants
L2343D, F2344A, S2345D, R2394E, E2395R, and S2409A were
shown to interfere with dimerization, while M2408E had little
influence on dimerization. The D2388K and H2391D mutants
did not express well. Consistent with the above analysis, the gel
filtration elution positions of the R2394E mutant showed delays
Fig. 2. Dimerization of the WD40 domain of LRRK2. (A) Ribbon diagram of the dimer in two orientations with the subunits in green and cyan, respectively.
(B) Detailed interactions at the dimer interface (Middle) with enlarged views at Left and Right. The residues in the symmetric subunit are marked with
apostrophe symbol. The residues with main chain atom interactions are shown in blue. (C) MALS measurements of WD40 domain of LRRK2 at 2 mg/mL (red)
and 0.25 mg/mL (blue), respectively. The absorption values at the left for the 0.25 mg/mL sample were multiplied 8× to scale with the absorption for the 2 mg/mL
sample. (D) Concentration-dependent dimerization of theWD40 domain. The concentrations of the injected samples are shown, showing the progressive delay in
elution at lower concentrations.








relative to the wild-type (WT) at all four tested concentrations
(SI Appendix, Fig. S3A).
A number of variations in the WD40 domain have been
reported in PD (5, 6) (www.molgen.ua.ac.be/PDmutDB/) (Fig.
3H). Y2189C (26), T2356I (27), and L2439I (28) are buried and
may disrupt the structural integrity. D2175H (28) and R2143H
(29) are mutations on exposed residues and may influence po-
tential interactions intramolecularly and with neighboring LRRK2
molecules or other proteins. G2385R (21, 22) and V2390M (30)
mutants are on residues at the dimer interface. When assayed for
dimerization using purified proteins, both G2385R and V2390M
disrupted dimerization of the LRRK2 WD40 domain (Fig. 3I and
SI Appendix, Fig. S3B and Table S3). Similarly, D2175H, T2356I,
and L2439I also compromised dimerization likely because they
altered the protein structure, while Y2189C did not affect the dimer
interaction (SI Appendix, Fig. S3 C–F and Table S3). The R2143H
variant did not express well. A recent study reported three addi-
tional WD40 variants N2308D, N2313S, and S2350I in the main-
land Chinese population (31). While residues N2308 and N2313 are
both disordered in the structure, S2350 is close to the dimerization
interface and may also affect WD40 domain dimerization (Fig. 3H).
Effects of LRRK2 WD40 Dimerization Mutations on Rab10 Phosphorylation.
The Rab family GTPases belonging to the Ras small GTPase
superfamily are important kinase substrates of LRRK2 (39),
which localize to exocytic and endocytic compartments to regu-
late intracellular vesicle trafficking (40). It has been shown that
LRRK2 directly phosphorylates a conserved Thr or Ser residue in
the effector-binding switch II motifs of Rab proteins, which in-
hibits the binding to the Rab GDP-dissociation inhibitor factors
that are required for membrane delivery and recycling (39). To
investigate the functional effect of LRRK2 WD40 dimerization,
we assessed the LRRK2 kinase activity using Rab10 phosphory-
lation on residue T73 using a recently elaborated specific anti-phospho-
Rab10 antibody (41), upon cotransfection of WT and mutant LRRK2
with Rab10 in HEK293 cells (42) (Fig. 4A and SI Appendix, Table S3).
LRRK2 autophosphorylation on S1292 (43) and phosphorylation at
the well-studied S935 biomarker site (44) were also determined. We
found that mutations at the dimerization interface, H2391D, R2394E,
and the disease-related G2385R, moderately enhanced Rab10 phos-
phorylation by about twofold, while the remaining mutants L2343D,
F2344A, S2345D, Y2346A, E2395R, and M2408A did not signifi-
cantly impact Rab10 phosphorylation (Fig. 4A). As a control, the
kinase-inactive LRRK2 mutant D2017A did not induce Rab10
phosphorylation. These results were confirmed by quantification
on the ratio of pRab10 phosphorylation over total Rab10 for three
independent experiments (Fig. 4B).
Because R1441G and G2019S are two recurrent PD variants,
we also generated the same sets of LRRK2 WD40 domain
mutations in these backgrounds. In the R1441G background,
addition of the LRRK2 WD40 domain mutations did not further
alter Rab10 phosphorylation (SI Appendix, Fig. S4 A and B). In
contrast, in the G2019S background, the LRRK2 WD40 domain
mutations exerted similar effects as in the WT background, with
Fig. 3. Effects of structure-based and PD-associated mutations in WD40 domain dimerization. (A–G) Elution positions of structure-based mutants in comparison
with the WT WD40 domain. Decreased: decreased dimerization; Increased: increased dimerization; Similar: no change in dimerization. (H) Ribbon diagram of
WD40 domain dimer with PD-associated mutations highlighted as balls with carbon atoms in yellow, nitrogen atoms in blue, and oxygen atoms in red. These
mutations are labeled in red if the mutations occur at the dimerization interface, black if the mutations are on buried residues, and blue if the mutations are on
exposed residues away from the dimerization interface. (I) Elution position of the G2385R disease mutant in comparison with the WT WD40 domain.
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H2391D, R2394E, and the disease-related G2385R moderately
increasing Rab10 phosphorylation (SI Appendix, Fig. S4 B and
C). It has been shown previously that G2019S mutation alone
does not change Rab10 phosphorylation (45). Only the R2394E
mutation consistently promoted LRRK2 phosphorylation on
S1292 above background, an event that is thought to be auto-
phosphorylation (43) (Fig. 4A and SI Appendix, Fig. S4 A–C). Of
note, previous studies reported that G2385R did not lead to an
obvious change in autophosphorylation (46) but clearly led to an
increase in Rab10 transphosphorylation (47). In contrast, phos-
phorylation on LRRK2 S935, which is thought to be regulated by
LRRK2 via potentially other kinases (44), was interestingly re-
duced for the disease-related G2385R mutant as well as the
kinase-inactive mutant D2017A, both in the WT and the G2019S
backgrounds (Fig. 4A and SI Appendix, Fig. S4 B and C). Con-
sistent with previous work, the R1441G mutation considerably
suppressed Ser935 phosphorylation (44). For LRRK2 WD40
mutations in the R1441G background, no obvious changes in
S935 phosphorylation were observed except slight enhancement
for the kinase-inactive mutant D2017A (SI Appendix, Fig. S4 A
and B). We also investigated the remaining WD40 domain
disease-associated variants on LRRK2 kinase activity using
Rab10 phosphorylation. In contrast to G2385R, these variants
did not cause a significant difference in Rab10 phosphorylation
(Fig. 4 C and D and SI Appendix, Fig. S4D and Table S3).
Enhanced LRRK2 kinase activity for some of the WD40 di-
merization defective mutants, including H2391D, R2394E, and
the disease variant G2385R, indicates that WD40 dimerization
may be inhibitory to the kinase activity. However, there is no
strict correlation between dimerization and LRRK2 kinase ac-
tivity, suggesting that dimerization is not the only factor in the
regulation of this complex enzyme.
Discussion
Despite the biological and clinical importance of LRRK2, lim-
ited structural information is currently available. Our WD40
domain structure contributes to improving this situation by
adding a high-resolution view of a second domain of human
LRRK2 after the previously determined structure of the ROC
domain of human LRRK2 (9). We found that the WD40 domain
forms dynamic dimers in solution, and both structure-based
mutations and PD-associated disease variants in the WD40 do-
main mainly impair its dimerization. Hence, our structure pro-
vides a template for elucidating the biological function of the
WD40 domain and for understanding how mutations of the
domain may affect the function of LRRK2.
Our structural and functional analysis here only touched the
surface of the complexity of LRRK2 biology. For one, di-
merization in the WD40 domain does not have a strict correla-
tion with LRRK2 kinase activity, as determined by Rab10
phosphorylation. Only three WD40 dimerization-defective mu-
tants enhanced LRRK2 kinase activity by about twofold, while
the other mutants did not show an obvious effect. One possible
scenario is that WD40 domain dimerization does play a role in
LRRK2 biological and pathological function but is not sufficient
on its own. Interestingly, in the low-resolution full-length, active
LRRK2 structure model, the WD40 domain is not adjacent to
each other for dimer formation (13, 14), suggesting that WD40
domain dimerization may be inhibitory. This is puzzling as the
kinase activity of full-length LRRK2 does appear to reside with
dimers (48), while GTPase activity of the ROC domain is equiv-
alent in dimers and monomers (49). Is it possible that there are at
least two different dimerization states of full-length LRRK2? A
WD40 domain-mediated dimer may be important for other in-
teractions by LRRK2 such as with microtubules (19). In fact, it is
unknown whether the WD40 domain mutations generated here
disrupt the dimerization of full-length LRRK2.
A completely different scenario is that the surface on blade V,
identified by mutants H2391D, R2394E, and the disease-related
G2385R, or the conserved top surface on blade III and IV (Fig.
1D), may be important for partner interactions by the WD40
domain (Fig. 2A and SI Appendix, Fig. S2). The blade V surface
partially overlaps with the WD40 dimerization interface, and it is
likely that this surface, as well as the conserved top surface, is
used for additional intramolecular or intermolecular interactions
to regulate LRRK2 function.
While further studies will be required to dissect these scenarios
to elucidate the exact role of theWD40 domain and its dimerization
Fig. 4. Effect of LRRK2 WD40 dimerization mutations and disease mutations on LRRK2 kinase activity. (A) HEK293 cells were transfected with the indicated
WT and mutant LRRK2 variants together with either HA-empty vector (Mock) or HA-tagged Rab10. Twenty-four hours after transfection, cells were lysed and
analyzed by immunoblotting with the indicated antibodies. From top to bottom: Rab10 phosphorylation at T73 (pRab10), LRRK2 autophosphorylation at
S1292 (pS1292), LRRK2 phosphorylation at S935 (pS935), total HA-Rab10 and endogenous Rab10, pRab10 and Rab10 overlay, total LRRK2, and the loading
control GAPDH. D2017A corresponds to the kinase-inactive LRRK2 mutant. Duplicated results are shown. (B) Quantification of pRab10 over total Rab10 in A.
The WT ratio is set at 1.0. Errors indicated mean ± STD for three independent experiments. (C) HEK293 cells were transfected with the indicated WT and
mutant LRRK2 variants together with HA-tagged Rab10. Twenty-four hours after transfection, cells were lysed and analyzed by immunoblotting with the
indicated antibodies. From top to bottom: Rab10 phosphorylation at T73 (pRab10), LRRK2 phosphorylation at S935 (pS935), total HA-Rab10, total LRRK2, and
the loading control GAPDH. D2017A corresponds to the kinase-inactive LRRK2 mutant. Duplicated results are shown. (D) Quantification of pRab10 over total
Rab10 in C. The WT ratio is set at 1.0. Errors indicated mean ± STD for three independent experiments.








in the function of LRRK2, our data clearly showed moderately
increased LRRK2 kinase activity for the PD-associated G2385R
variant. Hence, patients with WD40 mutations that are relatively
common in certain Asian populations might benefit from receiving
LRRK2 kinase inhibitors. These data also support the general
concept that like all other LRRK2 pathogenic mutations, WD40
mutations also result in activation of LRRK2 and promote Rab10
phosphorylation.
Materials and Methods
Protein Expression and Purification. Human LRRK2 WD40 domain (residues
2142–2527) was expressed in Sf9 insect cells via baculovirus infection and
purified to homogeneity.
Crystallization and Structure Determination. The LRRK2 WD40 domain was
crystallized using hanging drop vapor diffusion. The structure was determined
by anomalous diffraction phasing and refined to 2.6-Å resolution. The atomic
coordinates and structure factors have been deposited in the Protein Data
Bank, www.wwpdb.org [PDB ID codes 6DLO (50) and 6DLP (51)].
MALS. To measure the molecular mass of the WD40 domain protein in so-
lution, we used a three-angle light scattering detector and a refractive index
detector, which were coupled to a chromatography system.
Quantitative Immunoblot Analysis. Proteins were electrophoretically trans-
ferred onto nitrocellulose membrane. After incubation with antibodies,
protein bands were acquired via near infrared fluorescent detection using
Odyssey CLx imaging.
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